Гносеологические аспекты философской системы Н. О. Лосского
2011/01/01 by Kimberly D. Miller, Rebecca L. Siegel, Chun Chieh Lin +8 · 47 citations
Arts and Humanities · Medicine · Psychology · #Acute Lymphoblastic Leukemia research #Cancer #Cancer survivorship #Classical Philosophy and Thought #Cognition #Cognitive science #Computer science #Demography #Epistemology #Internal medicine #Intuition #Lung Cancer Treatments and Mutations #Medicine #Multiple and Secondary Primary Cancers #Object (grammar) #Philosophy #Psychology #Statistics #Subject (documents) #Survivorship curve
paper · doi:10.3322/caac.21349
published in Вестник Русской христианской гуманитарной академии 12(2), 271-89 (Wiley)
openalex publication_date 2011/01/01 · openalex created_date 2016/06/24 · openalex updated_date 2026/07/23
Abstract
The number of cancer survivors continues to increase because of both advances in early detection and treatment and the aging and growth of the population. For the public health community to better serve these survivors, the American Cancer Society and the National Cancer Institute collaborate to estimate the number of current and future cancer survivors using data from the Surveillance, Epidemiology, and End Results cancer registries. In addition, current treatment patterns for the most prevalent cancer types are presented based on information in the National Cancer Data Base and treatment-related side effects are briefly described. More than 15.5 million Americans with a history of cancer were alive on January 1, 2016, and this number is projected to reach more than 20 million by January 1, 2026. The 3 most prevalent cancers are prostate (3,306,760), colon and rectum (724,690), and melanoma (614,460) among males and breast (3,560,570), uterine corpus (757,190), and colon and rectum (727,350) among females. More than one-half (56%) of survivors were diagnosed within the past 10 years, and almost one-half (47%) are aged 70 years or older. People with a history of cancer have unique medical and psychosocial needs that require proactive assessment and management by primary care providers. Although there are a growing number of tools that can assist patients, caregivers, and clinicians in navigating the various phases of cancer survivorship, further evidence-based resources are needed to optimize care. CA Cancer J Clin 2016;66:271-289. © 2016 American Cancer Society.
Citations
Cited by
- Breast cancer statistics, 2019
- Breast cancer statistics, 2017, racial disparity in mortality by state
- Caring for caregivers and patients: Research and clinical priorities for informal cancer caregiving
- Prostate segmentation using Z-net
- Transoral robotic surgery hypopharyngectomy (TORSH): feasibility and outcomes
- Bacteria-based immune therapies for cancer treatment
- Computer-aided diagnosis for breast cancer classification using deep neural networks and transfer learning
- LvHemB1, a novel cationic antimicrobial peptide derived from the hemocyanin of Litopenaeus vannamei, induces cancer cell death by targeting mitochondrial voltage-dependent anion channel 1
- Celebrity disclosure prompts public discourse regarding appearance changes related to breast cancer care: a content analysis of Internet comments
- Impact of exercise on health outcomes in people with cancer: an umbrella review of systematic reviews and meta-analyses of randomised controlled trials
- Deep Learning in Multi-organ Segmentation
- The psychological impact of sarcoma on affected patients
- Sulforaphane epigenetically demethylates the CpG sites of the miR-9-3 promoter and reactivates miR-9-3 expression in human lung cancer A549 cells
- Artificial intelligence-derived left ventricular strain in echocardiography in patients treated with chemotherapy
- Fisetin and/or capecitabine causes changes in apoptosis pathways in capecitabine-resistant colorectal cancer cell lines
- Modern Radiotherapy and Risk of Cardiotoxicity
- Artificial intelligence in radiation oncology
- Targeted and Imaging-guided In Vivo Photodynamic Therapy of Tumors Using Dual-functional, Aggregation-induced Emission Nanoparticles
- Response Evaluation Following Radiation Therapy With 18F-FDG PET/CT: Common Variants of Radiation-Induced Changes and Potential Pitfalls
- Quantitative in vivo imaging to enable tumor forecasting and treatment optimization
- Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173 797 patients
- Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cells
- Association Between Choice of Radical Prostatectomy, External Beam Radiotherapy, Brachytherapy, or Active Surveillance and Patient-Reported Quality of Life Among Men With Localized Prostate Cancer. [europepmc]
- Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States. [europepmc]
- Cisplatin is retained in the cochlea indefinitely following chemotherapy. [europepmc]
- Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. [europepmc]
- Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. [europepmc]
- Efficacy of Exercise Therapy on Cardiorespiratory Fitness in Patients With Cancer: A Systematic Review and Meta-Analysis. [europepmc]
- Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. [europepmc]
- Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. [europepmc]
- Effect of Exercise and Nutrition Prehabilitation on Functional Capacity in Esophagogastric Cancer Surgery: A Randomized Clinical Trial. [europepmc]
- Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer. [europepmc]
- Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape. [europepmc]
- Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium. [europepmc]
- RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3. [europepmc]
- Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientific Statement From the American Heart Association. [europepmc]
- Physical Activity in Cancer Prevention and Survival: A Systematic Review. [europepmc]
- Annual Report to the Nation on the Status of Cancer, Featuring Cancer in Men and Women Age 20-49 Years. [europepmc]
- Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. [europepmc]
- Financial Burdens of Cancer Treatment: A Systematic Review of Risk Factors and Outcomes. [europepmc]
- Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable. [europepmc]
- Ovarian cancer cell-secreted exosomal miR-205 promotes metastasis by inducing angiogenesis. [europepmc]
- Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. [europepmc]
- Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy. [europepmc]
- RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m6A-YTHDF2-dependent manner. [europepmc]
- The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling. [europepmc]
- SLC7A11/xCT in cancer: biological functions and therapeutic implications. [europepmc]
Related